GlobeNewsWire
01 Sept 2026, 23:44 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
2 claims · each scored for market impact
Pomerantz LLP is investigating Abeona Therapeutics (ABEO) for potential securities fraud or unlawful business practices. — Legal investigations into securities fraud typically create significant downward pressure on stock prices due to litigation risk and reputational damage.
-0.60Abeona disclosed that one batch of its ZEVASKYN therapy lacked the minimum requirements for revenue recognition, leading to a 14.95% stock price drop on August 13, 2026. — Failure in commercial execution and revenue recognition for a primary therapy indicates operational weaknesses and affects near-term financial projections.
-0.40Which stocks this story touches
The company is under investigation for potential securities fraud following a stock price drop caused by revenue recognition issues.
Continue reading
6 related stories
Search tags
The company is the subject of a legal investigation by Pomerantz LLP on behalf of investors.
The company is the subject of a legal investigation by Pomerantz LLP on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
3h ago
